Which UK clinics offer ChondroFiller injection

Two clinic groups currently offer ChondroFiller® as an outpatient knee injection in the UK: London Cartilage Clinic at 66 Harley Street, London, and Lincolnshire Knee — part of the MSK Doctors group — at outpatient sites in Sleaford (NG34) and Grantham (NG31).

London Cartilage Clinic, led by Professor Paul Y.F. Lee, was the first UK site to deliver the treatment as an ultrasound-guided injection. It remains the most frequently cited provider across clinical and patient-facing sources. For patients who cannot travel to London, Lincolnshire Knee offers a genuine regional alternative with consultant-led outpatient access at both Lincolnshire sites — no GP referral is needed to book an initial assessment.

Beyond these two groups, equivalent ChondroFiller injection services are not widely published elsewhere in the UK. The provider landscape is small and specialist.

All access is self-funded and private. ChondroFiller is not commissioned by the NHS, and private medical insurance does not routinely cover it.

How the ChondroFiller injection works

ChondroFiller® is a cell-free Type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals GmbH in Germany. It carries a CE mark as a Class III medical device — the highest-risk category under European device regulation — which is why it is imported under prescription and administered by a specialist rather than in a general clinical setting.

The mechanism is described as acellular matrix-induced chondrogenesis. In plain terms: the scaffold itself contains no donor cells. Instead, once placed inside a focal cartilage defect, it provides a three-dimensional collagen structure that recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — to support the body's natural repair processes within that defect space. The gel sets in approximately three to five minutes after placement.

The procedure is an outpatient ultrasound-guided injection. There is no general anaesthetic, no surgical incision, and no theatre admission. Real-time ultrasound imaging guides accurate placement into the defect. The appointment typically takes around 30 to 45 minutes in total.

ChondroFiller is indicated for focal, full-thickness knee cartilage defects rather than widespread joint degeneration. Before treatment, a current MRI is reviewed to measure the defect and determine how many implant boxes are required — this sizing step is what shapes both suitability and cost. Patients with bone-on-bone osteoarthritis across the whole joint are generally less suitable, though a consultant assessment determines this on an individual basis.

The injection pathway vs. the Liquid Cartilage™ surgical procedure

Patients researching this treatment online sometimes encounter 'ChondroFiller injection' and 'Liquid Cartilage™' used as though they are the same thing. They are not — they are two clinically distinct procedures with different settings, different anaesthesia requirements, and different selection criteria.

The ChondroFiller outpatient injection — the current service pathway at Lincolnshire Knee — is delivered in a clinic room under real-time ultrasound guidance. There is no general anaesthetic and no surgical incision. No upper age limit or defect-size ceiling is stated for the injection route; suitability is determined at consultation.

Liquid Cartilage™ is a separate keyhole surgical procedure carried out under general anaesthetic as a day case. It combines ChondroFiller® scaffold placement with mesenchymal stem cell (MSC) co-delivery at a contained focal defect. Because it is a surgical pathway, it is offered at specific sites by specific teams and involves a different pre-operative assessment process.

The decision between these two pathways is not made by patient preference alone. It depends on the MRI defect pattern — its size, depth, and location — and on the patient's regenerative capacity as assessed at consultation. Where the injection pathway is clinically appropriate, that is what Lincolnshire Knee offers. If the clinical picture points towards the surgical route, a treating consultant will discuss that separately and advise on appropriate referral.

Booking a consultation: what to bring and what to expect

No GP referral is needed to book an initial assessment at Lincolnshire Knee — patients can contact the clinic directly, which matters when NHS waiting lists are a barrier to timely care.

Before or at the consultation, a current MRI of the affected knee is essential. Defect size in cm² determines how many implant boxes are required, so imaging is the practical starting point for any treatment plan. If a scan is not yet in hand, Lincolnshire Knee's Sleaford site (NG34) has an Open MRI on-site; the onMRI™ AI-driven analysis tool can assist with cartilage segmentation and defect characterisation, which supports more precise pre-treatment planning. The Grantham site (NG31) offers consultation and diagnostics for patients closer to that location.

At the appointment, the clinician reviews the MRI to confirm that the defect is focal and full-thickness, that the wider joint is in appropriate condition for the injection pathway, and that ChondroFiller is a clinically suitable option. Bone alignment, body weight, and activity level may also inform that assessment.

By the end of the consultation, patients typically leave with a clear answer on suitability, the number of boxes required (and therefore the guide cost), and a recommended next step — whether that is proceeding to the injection or considering an alternative approach.

Guide costs and what the price covers

Guide costs for ChondroFiller® at Lincolnshire Knee run from approximately £3,000 for a single-box treatment (focal defects of around 3 cm²), rising to £5,500 for two boxes (approximately 4.5 cm²) and £8,000 for three boxes (around 6 cm²); more complex Grade III/IV presentations may reach £9,800. Most patients presenting with a discrete focal knee defect fall into the single-box tier.

Every price tier is all-inclusive: the pre-injection consultation and MRI review, real-time ultrasound guidance, the ChondroFiller implant itself, IV antibiotic cover, the procedure, and a six-week follow-up are all bundled. There are no separately billed line items for these routine components of care.

The cost sits above standard lubricant injections because of ChondroFiller's device classification and prescription-import requirements (covered in section 2), not a clinic mark-up. The all-inclusive structure adds further context: patients are not paying a single procedure fee on top of separate consultation and imaging bills.

Because defect size and pattern — and therefore box count — are confirmed only after MRI review at consultation, the guide cost for an individual patient is finalised at that appointment rather than in advance. Confirm current pricing directly with Lincolnshire Knee when booking.

What the clinical evidence shows

More than 19,000 cases of ChondroFiller® have been treated globally, across specialist centres using both arthroscopic and injectable delivery routes.

For the knee, published clinical series report an average improvement of approximately 30 IKDC points at 12–36 months post-treatment. IKDC runs from 0 to 100, and a 30-point gain represents a clinically meaningful functional shift — broadly equivalent to moving from markedly limited to near-normal activity tolerance. Follow-up MRI in these series yields MOCART cartilage scores of 70–87, indicating a structural repair signal at the treated site rather than an empty defect or fibrocartilage substitution. The adverse event rate across the global case series is approximately 0.06%.

Two limitations deserve a plain statement. The 12–36-month window is where most published outcome data sit; durability beyond five years is poorly characterised, and that gap matters for any patient thinking about long-term joint preservation. The global case volume also spans multiple delivery routes, so the evidence base for the ultrasound-guided injectable pathway specifically is narrower than the headline figure implies.

For patients with a focal cartilage defect, what the current data support is meaningful functional and structural improvement over a one-to-three-year horizon — alongside an honest acknowledgement that the longer-term durability question is not yet settled. Whether that balance of evidence justifies proceeding is a clinical judgement that depends on defect size, age, activity demands, and the rate of progression if the defect is left untreated. A consultant assessment is the practical way to reach that answer; at Lincolnshire Knee, part of MSK Doctors, no GP referral is required to book one. lincolnshireknee.co.uk